By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Viking Therapeutics (VKTX) is a high-risk, high-reward play, with a significant risk of trial delays or adverse safety signals, and existential risk if Phase 3 trials fail. The company's primary opportunity lies in potential acquisition before its cash runway expires.
Risk: Phase 3 trial failure or delays
Opportunity: Potential acquisition before cash runway expires
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Theglobal marketfor drugs that treat obesity could be worth $150 billion by 2035.
Viking Therapeutics is developing a pill and an injectable version of its weight-loss candidate.
One recent Wall Street analyst's price target suggests shares could climb 188%.
An analyst at the banking giant Truist Financial has an $83 price target on Viking Therapeutics (NASDAQ: VKTX), which is particularly notable given that Viking opened at $28.75 per share on June 8. If it reached that target from that June 8 opening price, that would be a gain of 188%.
The clinical-stage company lacks commercial products, but it has a promising weight-loss drug candidate, VK2735, in phase 3 trials. The rewards for getting the drug to market could be substantial, which the bold price target reflects. But so too are the risks for investors.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
While there has been previous disappointment with trial results from Viking, the analyst from Truist views the company as a differentiated drugmaker in the space. Its injectable version in particular has been highlighted for its potential to provide both weight loss and favorable tolerability, which could help it stand out in a market that's growing but also increasingly crowded.
Researchers at Morgan Stanley project that theglobal marketfor drugs to treat obesity will grow from around $15 billion in sales in 2024 to $150 billion by 2035. Viking Therapeutics is gearing up to grab a slice of that potential cash pile, developing VK2735 in both oral and injectable forms. Currently, phase 3 for the injectable is in process, while the oral solution is expected to enter phase 3 in the third quarter of 2026, which is just around the corner.
The trials for both versions of VK2735 are evaluating its effectiveness as an obesity treatment. But getting it approved for one condition can be just the first step toward maximizing its sales potential, because weight loss drugs are being approved for uses beyond treating obesity. According to Motley Fool research on longevity investing:
GLP-1 drugs are expanding from weight loss into longevity territory. GLP-1s are a class of drugs that includes semaglutide, sold as Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro. Originally approved for diabetes and obesity, they have since received FDA [Food and Drug Administration] approval for cardiovascular risk reduction, obstructive sleep apnea, fatty liver disease, and oral obesity treatment.
The $83 price target from Truist makes Viking Therapeutics an enticing investment idea. But that upside also needs to be paired with the understanding that this stock carries significant risks. As a clinical-stage company, Viking is currently not generating any revenue.
If there are any issues in the trials for either version of VK2735, it will be a huge setback, removing the chance to get a revenue generator out the door. That's particularly important as losses mount. In 2024, Viking reported a net loss of $109 million, which climbed to $359 million in 2025. The company still has some runway, with $603 million in cash, cash equivalents, and short-term investments as of the end of March. That said, since it had $706 million at the end of 2025, it burned through $103 million in just three months.
There's a potential $150 billion market for Viking Therapeutics to capture, but investors will face significant volatility as they wait for it to receive approval to launch its first commercial product. The biggest risk is that such an approval may not arrive.
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,038! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,277,804!
Now, it’s worth noting Stock Advisor’s total average return is 942% — a market-crushing outperformance compared to 206% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 10, 2026. *
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Truist Financial. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Viking Therapeutics is currently a binary clinical-stage gamble where the current valuation leaves zero margin of safety for inevitable trial setbacks or future capital dilution."
Viking Therapeutics (VKTX) is a classic binary play masquerading as a long-term growth story. While the $150 billion obesity market projection is compelling, the stock is currently trading on pure speculative momentum rather than fundamental valuation. With a burn rate of $103 million per quarter and no commercial revenue, VKTX is effectively a high-stakes call option on Phase 3 trial results. The market is pricing in near-perfect clinical execution, ignoring the significant risk of trial delays or adverse safety signals which would necessitate dilutive equity raises. Unless you have a high tolerance for volatility and a specific horizon tied to FDA data readouts, the risk-to-reward ratio is currently skewed toward the downside.
Viking’s VK2735 could achieve 'best-in-class' status through superior tolerability profiles, potentially making it a prime acquisition target for Big Pharma players like Eli Lilly or Novo Nordisk looking to defend their GLP-1 duopoly.
"Viking's 188% upside target assumes flawless Phase 3 execution and market penetration in a duopoly-dominated space, but the company's 5.8-quarter cash runway makes trial failure or delayed approval an extinction event, not a recovery opportunity."
The $83 price target implies 188% upside from June 8 levels, but that math is deceptive—VKTX has likely moved since then, so the real upside is unknown. More critically: Viking is pre-revenue, burning $103M per quarter, with only 5.8 quarters of runway at current burn. Phase 3 failure on VK2735 is existential risk, not a setback. The $150B obesity market projection is real, but Novo Nordisk (NVO) and Eli Lilly (LLY) already own ~80% of the addressable space with approved, profitable drugs. Viking needs not just approval but differentiation *and* market share capture while cash depletes. The Truist target feels like it prices in best-case scenario without adequately weighting trial risk or competitive moat.
If VK2735 shows superior tolerability or weight-loss durability in Phase 3 (expected 2026-2027), it could command premium pricing and partnership deals that extend runway and derisk the company before cash runs out.
"Accelerating cash burn and a 2026 oral timeline leave VKTX exposed to dilution and competitive displacement well before any approval."
The $83 Truist target on VKTX implies massive upside from the June 8 open, but the article downplays that this clinical-stage firm posted a $359M net loss in 2025 while burning $103M in cash in the first quarter alone. Phase 3 for the injectable is underway, yet the oral candidate only enters pivotal trials in Q3 2026, giving established GLP-1 players years to entrench. With $603M in liquidity and no product revenue, any trial setback or slower enrollment risks repeated equity raises at uncertain valuations.
Strong phase 3 tolerability data could still differentiate VK2735 enough to secure a sizable slice of the projected $150B obesity market and expand into cardiovascular or liver indications faster than expected.
"Even with a promising pathway, the odds of Viking delivering revenue in a reasonable horizon remain uncertain, making the implied upside highly contingent on binary trial success and favorable regulatory and payer outcomes."
VKTX trades on a high-risk, high-reward thesis. The Truist $83 target implies ~188% upside from early June, and the obesity market's potential ($150B by 2035) is persuasive. But Viking is purely clinical-stage with no revenue; 2024-2025 losses rose to $109m and $359m with a cash cushion of $603m as of March, and burn dynamics imply more dilution unless a milestone or licensing deal materializes. Phase 3 for VK2735 oral is slated for Q3 2026, while the injectable faces competition from entrenched GLP-1 drugs, plus payer and pricing hurdles. Execution risk and regulatory timing could swamp the thesis.
Even with a successful Phase 3, the odds of Viking winning share against GLP-1 rivals and securing favorable payer coverage are nontrivial; the $83 target may be assuming near-perfect execution and licensing luck.
"Viking's valuation is driven by M&A optionality, making the cash runway a secondary concern compared to clinical data readouts."
Claude and Grok focus on cash burn, but they overlook the 'M&A premium' floor. Viking isn't going to market alone; they are a classic acquisition target. If VK2735 data holds, a buyout happens long before the 5.8-quarter runway expires. The real risk isn't dilution—it's the 'winner-take-all' dynamic where Big Pharma buys the patent to neutralize it. Investors aren't betting on commercialization; they are betting on a takeout premium before the cash crunch hits.
"M&A is a realistic exit, but the acquisition price won't bridge the valuation gap between Phase 3 optionality and current market cap."
Gemini's M&A floor argument is seductive but underestimates acquirer discipline. Lilly and Novo paid premiums for *approved* assets (Mounjaro, Saxenda). A Phase 3-stage oral won't command a $10B+ takeout—it's a $2-4B bolt-on at best. That doesn't justify current valuation. The 'neutralize the patent' thesis assumes Big Pharma fears Viking more than it fears paying $10B for optionality it may not need. That's backwards.
"Oral scarcity could drive takeout bids above Claude's $4B estimate via competitive bidding."
Claude's $2-4B takeout ceiling underestimates scarcity value of a differentiated oral GLP-1. With orals delayed until 2026 and injectables already entrenched, clean VK2735 tolerability data could draw bids from multiple non-Lilly/Novo players seeking pipeline entry, pushing premiums above current levels before the 5.8-quarter runway expires.
"The takeout premium is not guaranteed; data quality and licensing paths will largely determine VKTX's value, not a guaranteed buyout."
Gemini's 'M&A floor' overlooks how data quality drives bid levels. A phase 3 miss or only modest tolerability gains could leave VK2735 as a risky bolt-on; buyers will favor licensing deals or defensive collaborations to manage pipeline risk rather than pay a large premium. With a 5.8-quarter runway, a readout may trigger capital raises before any bid materializes, compressing upside. Durable, differentiating data and pricing power—not a guaranteed takeover—drive value.
Viking Therapeutics (VKTX) is a high-risk, high-reward play, with a significant risk of trial delays or adverse safety signals, and existential risk if Phase 3 trials fail. The company's primary opportunity lies in potential acquisition before its cash runway expires.
Potential acquisition before cash runway expires
Phase 3 trial failure or delays